Valuation: Fortress Biotech, Inc.

Market Cap 9.14Cr 7.91Cr 7.42Cr 6.76Cr 13Cr 871.31Cr 13Cr 87Cr 34Cr 436.28Cr 34Cr 34Cr 1.45TCr P/E 2026 *
1.15x
P/E 2027 * -5.5x
Enterprise Value 9.14Cr 7.91Cr 7.42Cr 6.76Cr 13Cr 871.31Cr 13Cr 87Cr 34Cr 436.28Cr 34Cr 34Cr 1.45TCr EV / Sales 2026 *
1.14x
EV / Sales 2027 * 0.74x
Free-Float
77.21%
Yield 2026 *
-
Yield 2027 * -
1 day+7.64%
1 week-1.43%
Current month-12.14%
1 month-16.67%
3 months+21.68%
6 months-21.20%
Current year-24.86%
1 week 2.57
Extreme 2.57
2.85
1 month 2.57
Extreme 2.57
3.84
Current year 2.18
Extreme 2.18
4.53
1 year 1.91
Extreme 1.911
4.53
3 years 1.24
Extreme 1.24
8.37
5 years 1.24
Extreme 1.24
57.15
10 years 1.24
Extreme 1.24
91.5
Manager TitleAgeSince
Chief Executive Officer 71 20/12/2013
Director of Finance/CFO 51 22/02/2012
Director of Finance/CFO 36 16/08/2022
Director TitleAgeSince
Director/Board Member 74 01/12/2008
Chairman 71 20/12/2013
Director/Board Member 63 01/06/2006
Date Insider Type Main position Quantity % Market Cap.
01/01/26 Free

Director

27,322 0.0880%
01/01/26 Free

Director

27,322 0.0880%
01/01/26 Free

Director

27,322 0.0880%
Change 5-day change 1-year change 3-year change Capi.($)
+7.64%-1.43%+36.82%-65.34% 9.14Cr
+0.05%+3.83%+43.38%-1.11% 7.97TCr
-3.73%+3.89%-1.33%+25.77% 5.06TCr
-0.81%-2.22%+15.61%+167.84% 4.88TCr
-0.66%+3.90%-48.98%-47.71% 4.69TCr
+0.78%+1.08%+62.00%-23.68% 3.09TCr
+0.22%+13.18%+148.13%-37.26% 2.54TCr
-0.07%+0.81%+47.98%+83.18% 2.45TCr
-0.42%+4.62%+0.16%+193.67% 2.12TCr
+0.01%+2.26%+70.79%+169.84% 1.64TCr
Average +0.39%+3.06%+37.46%+46.52% 3.44TCr
Weighted average by Cap. -0.60%+3.17%+28.67%+41.84%

Financials

2026 *2027 *
Net sales 7.99Cr 6.92Cr 6.48Cr 5.91Cr 11Cr 761.85Cr 11Cr 76Cr 30Cr 381.47Cr 30Cr 29Cr 1.27TCr 12Cr 11Cr 9.98Cr 9.11Cr 17Cr 1.17TCr 17Cr 117.44Cr 46Cr 587.42Cr 46Cr 45Cr 1.96TCr
Net income 9.05Cr 7.84Cr 7.35Cr 6.7Cr 13Cr 863.29Cr 13Cr 86Cr 34Cr 432.26Cr 34Cr 33Cr 1.44TCr -2.08Cr -1.81Cr -1.69Cr -1.54Cr -2.9Cr -198.75Cr -2.95Cr -20Cr -7.78Cr -100Cr -7.82Cr -7.65Cr -331.84Cr
Net Debt - -
Logo Fortress Biotech, Inc.
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Employees
78
Date Price Change Volume
13/26/13 $2.750 +5.36% 10,07,762
11/26/11 $2.610 -5.09% 6,17,236
10/26/10 $2.750 +3.00% 5,42,784
07/26/07 $2.670 -3.61% 5,79,990
06/26/06 $2.770 -0.72% 6,51,385
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.750USD
Average target price
11.00USD
Spread / Average Target
+300.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBIO Stock